Fore Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Fore Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,200	Closed	-$444K	–	72
2021 Q2	$444K	Buy	+2,200	New	+$460K	0.14%	54

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fore Capital's VRTX Position: Q3 2021 in Review

Fore Capital sold out of Vertex Pharmaceuticals (VRTX) in Q3 2021, closing a stake of 2,200 shares — an estimated $444K sold.

Fore Capital first reported a position in VRTX in Q2 2021 and held it in 1 quarter. The position peaked at $444K in Q2 2021. 935 funds tracked by Wall St. Rank hold VRTX as of Q3 2021.

Fore Capital reported no remaining Vertex Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Fore Capital sold 2,200 Vertex Pharmaceuticals shares in Q3 2021, an estimated $444K.
Fore Capital first reported a position in Vertex Pharmaceuticals in Q2 2021 and held it in 1 quarter.
Fore Capital's Vertex Pharmaceuticals position peaked at $444K in Q2 2021.
935 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2021.

Based on Fore Capital's 13F filing for Q3 2021, filed 12 Nov 2021.